Toll Free: 1-888-928-9744

Type 2 Diabetes - Pipeline Review, H1 2017

Published: May, 2017 | Pages: 1100 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Type 2 Diabetes - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 2 Diabetes - Pipeline Review, H1 2017, provides an overview of the Type 2 Diabetes (Metabolic Disorders) pipeline landscape.

Type 2 diabetes is a chronic condition and is the most common form of diabetes. High levels of glucose are a characteristic feature. The body might become resistant to insulin or may not produce enough amounts. Due to abnormal insulin functioning, glucose is concentrated in the blood leading to elevated levels and hence causing type 2 diabetes. Symptoms include fatigue, weight issues, vision deficits and various other effects. Risk factors include family history, age, obesity, physical inactivity and high blood pressure. This condition is handled by lifestyle alterations and regular medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Type 2 Diabetes - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Type 2 Diabetes (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 2 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 14, 1, 25, 68, 64, 5, 250, 75 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 1, 62 and 22 molecules, respectively.

Type 2 Diabetes (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Type 2 Diabetes (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Type 2 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Type 2 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Type 2 Diabetes (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Type 2 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents
2 Introduction 11 Type 2 Diabetes - Overview 12 Type 2 Diabetes - Therapeutics Development 13 Type 2 Diabetes - Therapeutics Assessment 67 Type 2 Diabetes - Companies Involved in Therapeutics Development 89 Type 2 Diabetes - Drug Profiles 198 Type 2 Diabetes - Dormant Projects 997 Type 2 Diabetes - Discontinued Products 1025 Type 2 Diabetes - Product Development Milestones 1035 Appendix 1043
List of Tables
Number of Products under Development for Type 2 Diabetes, H1 2017 69 Number of Products under Development by Companies, H1 2017 71 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 72 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 73 Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 74 Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017 75 Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017 76 Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017 77 Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017 78 Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017 79 Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017 80 Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017 81 Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017 82 Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017 83 Number of Products under Development by Companies, H1 2017 (Contd..13), H1 2017 84 Number of Products under Development by Companies, H1 2017 (Contd..14), H1 2017 85 Number of Products under Development by Universities/Institutes, H1 2017 86 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 88 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017 89 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017 90 Products under Development by Companies, H1 2017 91 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 92 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 93 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 94 Products under Development by Companies, H1 2017 (Contd..4), H1 2017 95 Products under Development by Companies, H1 2017 (Contd..5), H1 2017 96 Products under Development by Companies, H1 2017 (Contd..6), H1 2017 97 Products under Development by Companies, H1 2017 (Contd..7), H1 2017 98 Products under Development by Companies, H1 2017 (Contd..8), H1 2017 99 Products under Development by Companies, H1 2017 (Contd..9), H1 2017 100 Products under Development by Companies, H1 2017 (Contd..10), H1 2017 101 Products under Development by Companies, H1 2017 (Contd..11), H1 2017 102 Products under Development by Companies, H1 2017 (Contd..12), H1 2017 103 Products under Development by Companies, H1 2017 (Contd..13), H1 2017 104 Products under Development by Companies, H1 2017 (Contd..14), H1 2017 105 Products under Development by Companies, H1 2017 (Contd..15), H1 2017 106 Products under Development by Companies, H1 2017 (Contd..16), H1 2017 107 Products under Development by Companies, H1 2017 (Contd..17), H1 2017 108 Products under Development by Companies, H1 2017 (Contd..18), H1 2017 109 Products under Development by Companies, H1 2017 (Contd..19), H1 2017 110 Products under Development by Companies, H1 2017 (Contd..20), H1 2017 111 Products under Development by Companies, H1 2017 (Contd..21), H1 2017 112 Products under Development by Companies, H1 2017 (Contd..22), H1 2017 113 Products under Development by Companies, H1 2017 (Contd..23), H1 2017 114 Products under Development by Companies, H1 2017 (Contd..24), H1 2017 115 Products under Development by Companies, H1 2017 (Contd..25), H1 2017 116 Products under Development by Companies, H1 2017 (Contd..26), H1 2017 117 Products under Development by Universities/Institutes, H1 2017 118 Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017 119 Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017 120 Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017 121 Products under Development by Universities/Institutes, H1 2017 (Contd..4), H1 2017 122 Number of Products by Stage and Target, H1 2017 124 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 125 Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017 126 Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017 127 Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017 128 Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017 129 Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017 130 Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017 131 Number of Products by Stage and Mechanism of Action, H1 2017 133 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 134 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017 135 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017 136 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017 137 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017 138 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017 139 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017 140 Number of Products by Stage and Route of Administration, H1 2017 142 Number of Products by Stage and Molecule Type, H1 2017 144 Type 2 Diabetes - Pipeline by 4P Therapeutics LLC, H1 2017 145 Type 2 Diabetes - Pipeline by Addex Therapeutics Ltd, H1 2017 145 Type 2 Diabetes - Pipeline by Adocia, H1 2017 146 Type 2 Diabetes - Pipeline by Advinus Therapeutics Ltd, H1 2017 146 Type 2 Diabetes - Pipeline by Aegis Therapeutics LLC, H1 2017 147 Type 2 Diabetes - Pipeline by AFFiRiS AG, H1 2017 147 Type 2 Diabetes - Pipeline by Alize Pharma SAS, H1 2017 148 Type 2 Diabetes - Pipeline by Allergan Plc, H1 2017 148 Type 2 Diabetes - Pipeline by Alteogen Inc, H1 2017 149 Type 2 Diabetes - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017 149 Type 2 Diabetes - Pipeline by Amgen Inc, H1 2017 150 Type 2 Diabetes - Pipeline by Anchor Therapeutics Inc, H1 2017 150 Type 2 Diabetes - Pipeline by AntriaBio Inc, H1 2017 151 Type 2 Diabetes - Pipeline by Aphios Corp, H1 2017 151 Type 2 Diabetes - Pipeline by Araim Pharmaceuticals Inc, H1 2017 152 Type 2 Diabetes - Pipeline by Arena Pharmaceuticals Inc, H1 2017 152 Type 2 Diabetes - Pipeline by Arisaph Pharmaceuticals Inc, H1 2017 153 Type 2 Diabetes - Pipeline by ArisGen SA, H1 2017 153 Type 2 Diabetes - Pipeline by Astellas Pharma Inc, H1 2017 154 Type 2 Diabetes - Pipeline by AstraZeneca Plc, H1 2017 155 Type 2 Diabetes - Pipeline by AusBio Ltd, H1 2017 155 Type 2 Diabetes - Pipeline by Avadel Pharmaceuticals Plc, H1 2017 156 Type 2 Diabetes - Pipeline by Bayer AG, H1 2017 156 Type 2 Diabetes - Pipeline by Beta-Cell NV, H1 2017 157 Type 2 Diabetes - Pipeline by Betagenon AB, H1 2017 157 Type 2 Diabetes - Pipeline by Betta Pharmaceuticals Co Ltd, H1 2017 158 Type 2 Diabetes - Pipeline by Biocon Ltd, H1 2017 158 Type 2 Diabetes - Pipeline by BioLingus AG, H1 2017 159 Type 2 Diabetes - Pipeline by BioRestorative Therapies Inc, H1 2017 159 Type 2 Diabetes - Pipeline by Biozeus, H1 2017 160 Type 2 Diabetes - Pipeline by Biscayne Pharmaceuticals Inc, H1 2017 160 Type 2 Diabetes - Pipeline by Boehringer Ingelheim GmbH, H1 2017 161 Type 2 Diabetes - Pipeline by Boston Therapeutics Inc, H1 2017 161 Type 2 Diabetes - Pipeline by Braasch Biotech LLC, H1 2017 162 Type 2 Diabetes - Pipeline by Bristol-Myers Squibb Company, H1 2017 162 Type 2 Diabetes - Pipeline by C4X Discovery Holdings PLC, H1 2017 163 Type 2 Diabetes - Pipeline by Cadila Pharmaceuticals Ltd, H1 2017 163 Type 2 Diabetes - Pipeline by Cardax Inc, H1 2017 164 Type 2 Diabetes - Pipeline by Carmot Therapeutics Inc, H1 2017 164 Type 2 Diabetes - Pipeline by Celon Pharma SA, H1 2017 165 Type 2 Diabetes - Pipeline by Chipscreen Biosciences Ltd, H1 2017 165 Type 2 Diabetes - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017 166 Type 2 Diabetes - Pipeline by CJ HealthCare Corp, H1 2017 166 Type 2 Diabetes - Pipeline by CohBar Inc, H1 2017 167 Type 2 Diabetes - Pipeline by Concenter BioPharma Silkim Ltd, H1 2017 167 Type 2 Diabetes - Pipeline by ConjuChem LLC, H1 2017 168 Type 2 Diabetes - Pipeline by Connexios Life Sciences Pvt Ltd, H1 2017 168 Type 2 Diabetes - Pipeline by ConSynance Therapeutics Inc, H1 2017 169 Type 2 Diabetes - Pipeline by Corium International Inc, H1 2017 169 Type 2 Diabetes - Pipeline by CSL Ltd, H1 2017 170 Type 2 Diabetes - Pipeline by CureDM Inc, H1 2017 170 Type 2 Diabetes - Pipeline by CymaBay Therapeutics Inc, H1 2017 171 Type 2 Diabetes - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017 171 Type 2 Diabetes - Pipeline by Daiichi Sankyo Company Ltd, H1 2017 172 Type 2 Diabetes - Pipeline by Dance Biopharm Inc, H1 2017 172 Type 2 Diabetes - Pipeline by Delpor Inc, H1 2017 173 Type 2 Diabetes - Pipeline by Diabetology (Products) Ltd, H1 2017 173 Type 2 Diabetes - Pipeline by DiaMedica Therapeutics Inc, H1 2017 174 Type 2 Diabetes - Pipeline by Diamyd Medical AB, H1 2017 174 Type 2 Diabetes - Pipeline by Diasome Pharmaceuticals Inc, H1 2017 175 Type 2 Diabetes - Pipeline by DiscoveryBiomed Inc, H1 2017 175 Type 2 Diabetes - Pipeline by DNJ Pharma Inc, H1 2017 176 Type 2 Diabetes - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017 176 Type 2 Diabetes - Pipeline by Elcelyx Therapeutics Inc, H1 2017 177 Type 2 Diabetes - Pipeline by Eli Lilly and Company, H1 2017 177 Type 2 Diabetes - Pipeline by Enteris BioPharma Inc, H1 2017 178 Type 2 Diabetes - Pipeline by Enzo Biochem Inc, H1 2017 178 Type 2 Diabetes - Pipeline by Epichem Pty Ltd, H1 2017 179 Type 2 Diabetes - Pipeline by Esperion Therapeutics Inc, H1 2017 179 Type 2 Diabetes - Pipeline by Eternygen GmbH, H1 2017 180 Type 2 Diabetes - Pipeline by Evotec AG, H1 2017 180 Type 2 Diabetes - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017 181 Type 2 Diabetes - Pipeline by Generex Biotechnology Corp, H1 2017 181 Type 2 Diabetes - Pipeline by Genexine Inc, H1 2017 182 Type 2 Diabetes - Pipeline by Genfit SA, H1 2017 182 Type 2 Diabetes - Pipeline by Genmedica Therapeutics SL, H1 2017 183 Type 2 Diabetes - Pipeline by Genovate Biotechnology Co LTD, H1 2017 183 Type 2 Diabetes - Pipeline by Geropharm LLC, H1 2017 184 Type 2 Diabetes - Pipeline by Gilead Sciences Inc, H1 2017 184 Type 2 Diabetes - Pipeline by GlaxoSmithKline Plc, H1 2017 185 Type 2 Diabetes - Pipeline by Glide Pharmaceutical Technologies Ltd, H1 2017 185 Type 2 Diabetes - Pipeline by Glucox Biotech AB, H1 2017 186 Type 2 Diabetes - Pipeline by GW Pharmaceuticals Plc, H1 2017 186 Type 2 Diabetes - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2017 187 Type 2 Diabetes - Pipeline by HanAll Biopharma Co Ltd, H1 2017 187 Type 2 Diabetes - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017 188 Type 2 Diabetes - Pipeline by Heptares Therapeutics Ltd, H1 2017 188 Type 2 Diabetes - Pipeline by HitGen LTD, H1 2017 189 Type 2 Diabetes - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017 189 Type 2 Diabetes - Pipeline by Immuron Ltd, H1 2017 190 Type 2 Diabetes - Pipeline by Innopharmax Inc, H1 2017 190 Type 2 Diabetes - Pipeline by Innovative Targeting Solutions Inc, H1 2017 191 Type 2 Diabetes - Pipeline by Intarcia Therapeutics Inc, H1 2017 191 Type 2 Diabetes - Pipeline by Intas Pharmaceuticals Ltd, H1 2017 192 Type 2 Diabetes - Pipeline by Integral Molecular Inc, H1 2017 192 Type 2 Diabetes - Pipeline by Intercept Pharmaceuticals Inc, H1 2017 193 Type 2 Diabetes - Pipeline by Intrexon Corp, H1 2017 193 Type 2 Diabetes - Pipeline by Ionis Pharmaceuticals Inc, H1 2017 194 Type 2 Diabetes - Pipeline by Ironwood Pharmaceuticals Inc, H1 2017 194 Type 2 Diabetes - Pipeline by Islet Sciences Inc, H1 2017 195 Type 2 Diabetes - Pipeline by Japan Tobacco Inc, H1 2017 195 Type 2 Diabetes - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017 196 Type 2 Diabetes - Pipeline by Jenrin Discovery Inc, H1 2017 196 Type 2 Diabetes - Pipeline by JHL Biotech Inc, H1 2017 197 Type 2 Diabetes - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1 2017 197 Type 2 Diabetes - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017 198 Type 2 Diabetes - Pipeline by Johnson & Johnson, H1 2017 199 Type 2 Diabetes - Pipeline by Kadimastem Ltd, H1 2017 200 Type 2 Diabetes - Pipeline by Kadmon Corp LLC, H1 2017 200 Type 2 Diabetes - Pipeline by Kareus Therapeutics SA, H1 2017 201 Type 2 Diabetes - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017 201 Type 2 Diabetes - Pipeline by Lead Discovery Center GmbH, H1 2017 202 Type 2 Diabetes - Pipeline by Leading BioSciences Inc, H1 2017 202 Type 2 Diabetes - Pipeline by Lexicon Pharmaceuticals Inc, H1 2017 203 Type 2 Diabetes - Pipeline by LG Chem, Ltd., H1 2017 203 Type 2 Diabetes - Pipeline by Ligand Pharmaceuticals Inc, H1 2017 204



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2500
Multi User - US $5000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify